Abstract
A series of N-aroylated isatins 1-15 was synthesized and evaluated for their antiglycation activity. All compounds showed a varying degree of glycation inhibitory activity with IC50 values between 18.01 ± 0.05-693.7 ± 3.0 μM, when compared with the standard (aminoguanidine) having an IC50 = 268.7 ± 12.4 μM. Compound 1 was found to be the most active member of this series with an IC50 = 18.01 ± 0.05 μM. Compound 10 showed an IC50 = 72.5 ± 0.09 μM, whereas compound 7 has an IC50 = 80.18 ± 0.07 μM. Compounds 3, 9, and 13 showed IC50 values 170.2 ± 0.62, 117.91 ± 2.9, 171.3 ± 0.79 μM, respectively. Rest of the compounds along with parent isatin were found to be inactive. The structures of all the synthetic compounds were deduced by spectroscopic analysis.
Keywords: Isatin, N-Aroylation, Antiglycation, Lead molecules
Letters in Drug Design & Discovery
Title: N-Aroylated Isatins: Antiglycation Activity
Volume: 7 Issue: 3
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Ambreen Khan, Farzana Naz, Shahnaz Perveen and M. Iqbal Choudhary
Affiliation:
Keywords: Isatin, N-Aroylation, Antiglycation, Lead molecules
Abstract: A series of N-aroylated isatins 1-15 was synthesized and evaluated for their antiglycation activity. All compounds showed a varying degree of glycation inhibitory activity with IC50 values between 18.01 ± 0.05-693.7 ± 3.0 μM, when compared with the standard (aminoguanidine) having an IC50 = 268.7 ± 12.4 μM. Compound 1 was found to be the most active member of this series with an IC50 = 18.01 ± 0.05 μM. Compound 10 showed an IC50 = 72.5 ± 0.09 μM, whereas compound 7 has an IC50 = 80.18 ± 0.07 μM. Compounds 3, 9, and 13 showed IC50 values 170.2 ± 0.62, 117.91 ± 2.9, 171.3 ± 0.79 μM, respectively. Rest of the compounds along with parent isatin were found to be inactive. The structures of all the synthetic compounds were deduced by spectroscopic analysis.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Mughal Rasool Uzma, Khan Ambreen, Naz Farzana, Perveen Shahnaz and Choudhary Iqbal M., N-Aroylated Isatins: Antiglycation Activity, Letters in Drug Design & Discovery 2010; 7 (3) . https://dx.doi.org/10.2174/157018010790596597
DOI https://dx.doi.org/10.2174/157018010790596597 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Oxidative Stress Component in the Therapeutics of Epilepsy
Current Topics in Medicinal Chemistry Preface
Current Enzyme Inhibition Prostate-specific Antigen Levels in Moroccan Diabetic Males: A Cross-sectional Study
Current Diabetes Reviews Caffeic Acid Phenethyl Ester Restores Adipocyte Gene Profile Expression Following Lipopolysaccharide Treatment
Letters in Drug Design & Discovery ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Current Pharmaceutical Design Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets Exploring Natural Products as a Source for Antidiabetic Lead Compounds and Possible Lead Optimization
Current Topics in Medicinal Chemistry Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension
Current Hypertension Reviews Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Current Drug Targets The Application of Freidinger Lactams and their Analogs in the Design of Conformationally Constrained Peptidomimetics
Current Medicinal Chemistry